Eli Lilly And Co (NYSE:LLY) is scheduled to post its quarterly earnings results before the market opens on Tuesday, November 6th. Analysts expect Eli Lilly And Co to post earnings of $1.36 per share for the quarter.
Shares of Eli Lilly And Co stock opened at $106.75 on Friday. Eli Lilly And Co has a one year low of $73.69 and a one year high of $116.61. The stock has a market capitalization of $114.65 billion, a P/E ratio of 24.94, a PEG ratio of 1.73 and a beta of 0.29. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.40 and a quick ratio of 1.09.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be given a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a yield of 2.11%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s payout ratio is 52.57%.
In other news, major shareholder Eli & Co Lilly sold 4,531 shares of the business’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $14.33, for a total value of $64,929.23. Following the transaction, the insider now owns 3,934,137 shares in the company, valued at approximately $56,376,183.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 195,000 shares of the business’s stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $102.15, for a total value of $19,919,250.00. Following the completion of the transaction, the insider now owns 120,735,804 shares in the company, valued at approximately $12,333,162,378.60. The disclosure for this sale can be found here. Insiders sold a total of 1,380,271 shares of company stock worth $143,763,002 in the last 90 days. Company insiders own 0.11% of the company’s stock.
A number of analysts recently commented on the company. Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a research report on Wednesday, July 18th. Bank of America boosted their target price on Eli Lilly And Co from $90.00 to $94.00 and gave the company a “neutral” rating in a research report on Wednesday, July 25th. TheStreet downgraded Eli Lilly And Co from a “b” rating to a “c+” rating in a research note on Friday, August 24th. Cantor Fitzgerald set a $110.00 price target on Eli Lilly And Co and gave the company a “buy” rating in a research note on Monday, September 17th. Finally, BMO Capital Markets lifted their price target on Eli Lilly And Co from $80.00 to $90.00 and gave the company a “market perform” rating in a research note on Wednesday, July 25th. They noted that the move was a valuation call. Seven analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Eli Lilly And Co presently has an average rating of “Buy” and an average price target of $111.53.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: What is the NASDAQ Stock Market?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.